Accelerating TB vaccine Research & Development through partnership
Home
News
Projects
Projects
For researchers and vaccine developers
Partners pages
Access to services
MTBVAC in Newborns
Coordinator and partners
Communication tools
News and Publications
MTBVACN3
Work packages
Governance
The consortium and its partners
Publications and news
Acknowledgement
TBVAC-HORIZON
TBVAC2020
Word from the chair
TBVAC2020 project overview and achievements
TBVAC2020 project members
TBVAC2020 scientific publications
TBVAC2020 other publications
TBVI R&D priorities and funding opportunities
TBVI service provision and funding opportunities
Why invest in TBVI
ITHEMYC
Project overview
Consortium partners
News and Publications
Partners
About us
TBVI at a glance
Mission
Organisation
Governance Board
Advisory Committee
Steering Committee
Operational Office
Product and Clinical Development Team
TBVI consortium
Key achievements and impact
Financials
Policies
What we do
Pipeline of vaccines
Research & Development
Services
How we work
Business model
Partnership
Contact us:
Spanish vaccine agaisnt TB begins Phase 3
Home
/
Uncategorized
/
MTBVAC, the first vaccine against Tuberculosis derived from a human source, begins clinical trials in adults in India.
/ Spanish vaccine agaisnt TB begins Phase 3
Spanish vaccine agaisnt TB begins Phase 3
0
Start typing and press Enter to search
Cookies
This website uses cookies that help the website function
OK
No
